Drug Profile
Research programme: cardiovascular disease diagnostic agents - Kereos/Lantheus Medical Imaging
Alternative Names: KI-0002Latest Information Update: 04 Nov 2017
Price :
$50
*
At a glance
- Originator Kereos
- Developer Kereos; Lantheus Medical Imaging
- Class Diagnostic agents
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Cardiovascular disorders
Most Recent Events
- 04 Nov 2017 No recent reports of development identified for preclinical development in Cardiovascular-disorders(Diagnosis) in USA (Injection)
- 31 May 2010 Preclinical development of KI 0002 as an MRI agent for use in the assessment of CVD is ongoing in the US
- 08 Jan 2008 Bristol-Myers Squibb Medical Imaging has been acquired by Avista Capital Partners, and is now known as Lantheus Medical Imaging